Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study

Hu, Y.-D.; Xiang, Y.-T.; Fang, J.-X.; Zu, S.; Sha, S.; Shi, H.; Ungvari, G. S.; Correll, C. U.; Chiu, H. F. K.; Xue, Y.; Tian, T.-F.; Wu, A.-S.; Ma, X.; Wang, G.

doi:10.1017/s0033291715002159

Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study

Background While oral antidepressants reach efficacy after weeks, single-dose intravenous (i.v.) ketamine has rapid, yet time-limited antidepressant effects. We aimed to determine the efficacy and safety of single-dose i.v. ketamine augmentation of escitalopram in major depressive disorder (MDD).…